XENE — Xenon Pharmaceuticals Inc.

Summary of Xenon Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash, cash equivalents, and marketable securities totaled $555.3 million as of September 30, 2025, down from $754.4 million at the end of 2024.
• The company anticipates sufficient cash to fund operations into 2027, supporting multiple registrational programs.

2. Strategic Updates and Business Highlights:

• Xenon is focused on three key priorities:
  1. Completing the Phase III X-TOLE2 study of azetukalner for focal onset seizures, with top-line data expected in early 2026.
  2. Expanding azetukalner's therapeutic applications into neuropsychiatric indications, specifically major depressive disorder (MDD) and bipolar depression (BPD).
  3. Advancing early-stage programs targeting Nav1.7 and Kv7 ion channels, with both lead molecules now in Phase I studies.
• The company has exceeded its patient enrollment target in the X-TOLE2 study, randomizing 380 patients instead of the planned 360.
• Xenon presented data at the International Epilepsy Congress and plans to showcase further findings at the American Epilepsy Society meeting.

3. Forward Guidance and Outlook:

• The company remains optimistic about a positive outcome from the X-TOLE2 study, which is expected to support an NDA filing for azetukalner.
• Xenon is preparing for the potential launch of azetukalner in 2027, contingent on successful Phase III results.
• The company plans to provide additional guidance on the timing of top-line data as the study progresses.

4. Challenges and Points of Concern:

• The decline in cash reserves raises questions about future funding and operational sustainability, although management reassures that they have sufficient funds until 2027.
• Increased competition in the epilepsy treatment space, with other companies releasing early Phase II data, may pressure azetukalner's market positioning.
• The company has not disclosed specific screen failure rates for the X-TOLE2 study, which may raise concerns about patient selection and study robustness.

5. Notable Q&A Insights:

• Management indicated that the top-line data from X-TOLE2 will include key efficacy endpoints and safety data, similar to previous Phase II results.
• There was discussion about the impact of cenobamate usage on the X-TOLE2 study, with expectations that its use will be higher compared to Phase II.
• The interim analysis for the X-CEED trial in BPD was justified due to the lack of precedent data, contrasting with the MDD studies where prior proof-of-concept data was available.
• Questions regarding the selectivity of Nav1.7 inhibitors were met with assurance of high selectivity over other sodium channels, with further data expected in the future.

Overall, Xenon Pharmaceuticals is positioned for significant milestones in the coming year, with a focus on advancing its clinical programs while navigating competitive pressures and financial management.